<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03735667</url>
  </required_header>
  <id_info>
    <org_study_id>S2408</org_study_id>
    <nct_id>NCT03735667</nct_id>
  </id_info>
  <brief_title>ACURATE IDE: Safety and Efficacy Study of Acurate Valve for Transcatheter Aortic Valve Replacement</brief_title>
  <official_title>ACURATE IDE: Transcatheter Replacement of Stenotic Aortic Valve Through Implantation of ACURATE in Subjects InDicatEd for TAVR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate safety and effectiveness of the ACURATE Transfemoral Aortic Valve System for&#xD;
      transcatheter aortic valve replacement (TAVR) in subjects with severe native aortic stenosis&#xD;
      who are indicated for TAVR.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be enrolled at up to 85 centers in the United States, Canada, Europe, and&#xD;
      Australia. There will be up to 1,670 subjects in ACURATE IDE.&#xD;
&#xD;
      The ACURATE IDE study cohorts include the following.&#xD;
&#xD;
        -  Randomized Cohort: A prospective, multicenter, 1:1 randomized controlled trial (RCT;&#xD;
           ACURATE versus a commercially available balloon-expandable SAPIEN 3™ Transcatheter Heart&#xD;
           Valve or future iteration [SAPIEN 3; Edwards Lifesciences LLC, Irvine, CA, USA] or a&#xD;
           commercially available self-expanding CoreValve® Transcatheter Aortic Valve Replacement&#xD;
           System, CoreValve® Evolut™ R Recapturable TAVR System, EVOLUT™ PRO System, or future&#xD;
           iteration [CoreValve; Medtronic, Inc., Dublin, Ireland]). There will be up to 1,500&#xD;
           subjects in the RCT.&#xD;
&#xD;
        -  Roll-In Cohort: A non-randomized roll-in phase with the test device. Centers that do not&#xD;
           have implantation experience with the ACURATE neo™ Aortic Bioprosthesis (transfemoral&#xD;
           delivery; Boston Scientific Corporation, Marlborough, MA, USA) will perform at least 2&#xD;
           roll-in cases before commencing treatment in the randomized cohort. Centers with prior&#xD;
           experience with ACURATE are not required to do roll-in cases. Data from roll-in subjects&#xD;
           will be summarized separately from the randomized cohort and will not be included in the&#xD;
           primary endpoint analysis.&#xD;
&#xD;
        -  4D CT Imaging Substudy: Selected centers with the ability to perform high quality 4D&#xD;
           computer tomography (CT) scans will include subjects in a 4D CT Imaging Substudy to&#xD;
           assess the prevalence of reduced leaflet mobility and hypoattenuated leaflet thickening&#xD;
           (HALT) and the relationship, if any, to clinical events. Subjects will be randomized to&#xD;
           test (ACURATE) and control device.&#xD;
&#xD;
      All subjects implanted will be followed at baseline, peri- and post-procedure, at discharge&#xD;
      or 7 days post-procedure (whichever comes first), 30 days, 6 months, and then annually for up&#xD;
      to 10 years post-procedure. Enrolled subjects who do not have a study device implanted will&#xD;
      be assessed through 1-year post-procedure for safety/adverse events.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 10, 2019</start_date>
  <completion_date type="Anticipated">February 2033</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite rate of all-cause mortality, all stroke, and rehospitalization at 1 year.</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 1 year</time_frame>
    <description>Primary Effectiveness Endpoint; A Clinical Events Committee (CEC), independent group of physician experts was used to evaluate all reported cases of death and stroke to determine whether they met the specific protocol definition of the event. It is the CEC adjudicated result that is used in the endpoint analysis.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Mortality: all-cause, cardiovascular, and non-cardiovascular</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 years.</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Stroke: disabling and non-disabling</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 years.</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Myocardial infarction (MI): periprocedural (≤72 hours post index procedure) and spontaneous (&gt;72 hours post index procedure)</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 years.</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Bleeding: life-threatening (or disabling) and major</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4 and 5 years.</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Major vascular complications</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4 and 5 years.</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with a repeat procedure for valve-related dysfunction (surgical or interventional therapy)</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 years.</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants with hospitalization for valve-related symptoms or worsening congestive heart failure (NYHA class III or IV)</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 years.</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with new permanent pacemaker implantation resulting from new or worsened conduction disturbances</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 years.</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with new onset of atrial fibrillation or atrial flutter</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 years.</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with Acute kidney injury (AKI; ≤7 days post index procedure): based on the AKIN System Stage 3 (including renal replacement therapy) or Stage 2</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 7 days post index procedure.</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with Coronary obstruction: periprocedural</measure>
    <time_frame>Participants will be followed through 72 hours post index procedure</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with Ventricular septal perforation</measure>
    <time_frame>Participants will be followed through 72 hours post index procedure</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with Mitral apparatus damage: periprocedural</measure>
    <time_frame>Participants will be followed through 72 hours post index procedure</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with Cardiac tamponade: periprocedural</measure>
    <time_frame>Participants will be followed through 72 hours post index procedure</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with Valve migration</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 years.</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with Valve embolization</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 years.</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with Ectopic valve deployment</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 years.</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with Transcatheter aortic valve (TAV)-in-TAV deployment</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 years.</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with Prosthetic aortic valve thrombosis</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 years.</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with Prosthetic aortic valve endocarditis</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 6, 7, 8, 9 and 10 years.</time_frame>
    <description>Safety endpoint adjudicated by an independent Clinical Events Committee (CEC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with Successful vascular access, delivery and deployment of the study valve, and successful retrieval of the delivery system (site reported assessment)</measure>
    <time_frame>Participants will be followed for the duration of their procedure, an expected average of 1 day (peri- and post-procedure)</time_frame>
    <description>Device Performance endpoint, as measured by site reported data</description>
  </other_outcome>
  <other_outcome>
    <measure>Grade of aortic valve regurgitation: paravalvular, central and combined (echocardiographic assessment)</measure>
    <time_frame>Participants will be followed for the duration of their procedure, an expected average of 1 day (peri- and post-procedure)</time_frame>
    <description>Device Performance endpoint, as assessed by Echocardiographic Core Laboratory</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of participants with Device Success</measure>
    <time_frame>Participants will be followed for the duration of their procedure, an expected average of 1 day (post-procedure)</time_frame>
    <description>Absence of procedural mortality, correct positioning of a single transcatheter valve in the proper anatomical location, and intended performance of the study device (indexed effective orifice area [iEOA] &gt;0.85 cm2/m2 for BMI &lt;30 kg/cm2 and iEOA &gt;0.70 cm2/m2 for BMI ≥30 kg/cm2 plus either a mean aortic valve gradient &lt;20 mm Hg or a peak velocity &lt; 3m/sec, and no moderate or severe prosthetic valve aortic regurgitation)</description>
  </other_outcome>
  <other_outcome>
    <measure>Prosthetic aortic valve performance; Effective Orifice Area (EOA</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 7 and 10 years.</time_frame>
    <description>Effective Orifice Area (EOA), as measured by transthoracic echocardiography (TTE) and assessed by an independent core laboratory</description>
  </other_outcome>
  <other_outcome>
    <measure>Prosthetic aortic valve performance; Mean Aortic Gradient</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 7 and 10 years.</time_frame>
    <description>Mean aortic gradient as measured by transthoracic echocardiography (TTE) and assessed by an independent core laboratory</description>
  </other_outcome>
  <other_outcome>
    <measure>Prosthetic aortic valve performance; Peak Aortic Gradient</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 7 and 10 years.</time_frame>
    <description>Peak Aortic Gradient as measured by transthoracic echocardiography (TTE) and assessed by an independent core laboratory</description>
  </other_outcome>
  <other_outcome>
    <measure>Prosthetic aortic valve performance; Peak Aortic Velocity</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 7 and 10 years.</time_frame>
    <description>Peak Aortic Velocity as measured by transthoracic echocardiography (TTE) and assessed by an independent core laboratory</description>
  </other_outcome>
  <other_outcome>
    <measure>Prosthetic aortic valve performance; Grade of Aortic Regurgitation</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 7 and 10 years.</time_frame>
    <description>Grade of Aortic Regurgitation as measured by transthoracic echocardiography (TTE) and assessed by an independent core laboratory</description>
  </other_outcome>
  <other_outcome>
    <measure>New York Heart Association (NYHA) Functional Status classification</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4, 5, 7 and 10 years.</time_frame>
    <description>Evaluated by New York Heart Association (NYHA) classification</description>
  </other_outcome>
  <other_outcome>
    <measure>Neurological status; National Institutes of Health Stroke Scale (NIHSS) Assessment</measure>
    <time_frame>Participants will be followed at discharge and 1 year.</time_frame>
    <description>- National Institutes of Health Stroke Scale (NIHSS) at discharge and 1 year</description>
  </other_outcome>
  <other_outcome>
    <measure>Neurological status; Modified Rankin Scale (mRS) Assessment</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 6 months, and 1, 2, 3, 4 and 5 years.</time_frame>
    <description>- Modified Rankin Scale (mRS) at discharge and all follow-up visits through 5 years</description>
  </other_outcome>
  <other_outcome>
    <measure>Neurological status; Neurological physical exam assessment</measure>
    <time_frame>Participants will be followed for the duration of the trial, through 10 years.</time_frame>
    <description>- Neurological physical exam in all subjects where stroke is suspected</description>
  </other_outcome>
  <other_outcome>
    <measure>Health Status; Kansas City Cardiomyopathy Quality of Life questionnaire Assessment</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 1 and 5 years.</time_frame>
    <description>Evaluated by Kansas City Cardiomyopathy Quality of Life questionnaire</description>
  </other_outcome>
  <other_outcome>
    <measure>Health Status; SF-12 Quality of Life questionnaire Assessment</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, through 30 days, 1 and 5 years.</time_frame>
    <description>Evaluated by SF-12 Quality of Life questionnaire</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1670</enrollment>
  <condition>Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>ACURATE Valve - Randomized</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients assigned to this group will be implanted with ACURATE neo2™ transfemoral TAVR System.&#xD;
*A subset of subjects will also be enrolled in the 4D CT Imaging Substudy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACURATE Valve - Single-arm Roll-in</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients assigned to this group will be implanted with ACURATE neo2™ transfemoral TAVR System.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Commercial Valve - Randomized</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medtronic CoreValve TAVR System OR, Edwards SAPIEN 3 TAVR System&#xD;
Patients assigned to this group will be implanted with commercially available balloon-expandable SAPIEN 3™ Transcatheter Heart Valve or future iteration (SAPIEN 3; Edwards Lifesciences LLC, Irvine, CA, USA) or a commercially available self-expanding CoreValve® Transcatheter Aortic Valve Replacement System, CoreValve® Evolut™ R Recapturable TAVR System, EVOLUT™ PRO System, or future iteration (CoreValve; Medtronic, Inc., Dublin, Ireland) TAVR device.&#xD;
*A minimum of 200 subjects will also be enrolled in the 4D CT Imaging Substudy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ACURATE neo2™ Transfemoral TAVR System</intervention_name>
    <description>ACURATE neo2™ Transfemoral TAVR system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to limit paravalvular regurgitation (manufactured by Boston Scientific Corporation, Marlborough, MA, USA).</description>
    <arm_group_label>ACURATE Valve - Randomized</arm_group_label>
    <arm_group_label>ACURATE Valve - Single-arm Roll-in</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Medtronic CoreValve TAVR System</intervention_name>
    <description>Medtronic CoreValve Evolut R or Evolut PRO Transcatheter Aortic Valve Replacement (TAVR) System (or any future Corevalve iterations): The support frame is manufactured from nitinol, which has multilevel, self-expanding properties and is radiopaque. The bioprosthesis is manufactured by suturing valve leaflets and a skirt from porcine pericardium into a tri-leaflet configuration (manufactured by Medtronic CoreValve LLC, Santa Ana, USA).</description>
    <arm_group_label>Commercial Valve - Randomized</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Edwards SAPIEN 3 TAVR System</intervention_name>
    <description>Edwards SAPIEN 3 TAVR system (or any future SAPIEN iterations): balloon-expandable transcatheter aortic bioprosthesis, support frame made of cobalt-chromium, three leaflets constructed of processed bovine pericardial tissue and an outer polyethylene terephthalate (PET) sealing cuff to mitigate paravalvular regurgitation (manufactured by Edwards Lifesciences, Inc., Irvine, California, USA)</description>
    <arm_group_label>Commercial Valve - Randomized</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  IC1. Subject has documented severe symptomatic native aortic stenosis defined as&#xD;
             follows: aortic valve area (AVA) ≤1.0 cm2 (or AVA index ≤0.6 cm2/m2) AND a mean&#xD;
             pressure gradient ≥40 mmHg, OR maximal aortic valve velocity ≥4.0 m/s, OR Doppler&#xD;
             velocity index ≤0.25 as measured by echocardiography and/or invasive hemodynamics.&#xD;
&#xD;
        Note: In cases of low flow, low gradient aortic stenosis with left ventricular dysfunction&#xD;
        (ejection fraction &lt;50%), dobutamine can be used to assess the grade of aortic stenosis&#xD;
        (maximum dobutamine dose of 20 mcg/kg/min recommended); the subject may be enrolled if&#xD;
        echocardiographic criteria are met with this augmentation.&#xD;
&#xD;
          -  IC2. Subject has a documented aortic annulus size of ≥21 mm and ≤27 mm based on the&#xD;
             center's assessment of pre-procedure diagnostic imaging (and confirmed by the Case&#xD;
             Review Committee [CRC]) and, for the randomized cohort, is deemed treatable with an&#xD;
             available size of both test and control device.&#xD;
&#xD;
          -  IC3. For subjects with symptomatic aortic valve stenosis per IC1 definition above,&#xD;
             functional status is NYHA Functional Class ≥ II.&#xD;
&#xD;
          -  IC4. Heart team (which must include an experienced cardiac interventionalist and an&#xD;
             experienced cardiac surgeon) agrees that the subject is indicated for TAVR, is likely&#xD;
             to benefit from valve replacement, and TAVR is appropriate.&#xD;
&#xD;
          -  IC5. Subject (or legal representative) understands the study requirements and the&#xD;
             treatment procedures, and provides written informed consent.&#xD;
&#xD;
          -  IC6. Subject, family member, and/or legal representative agree(s) and subject is&#xD;
             capable of returning to the study hospital for all required scheduled follow up&#xD;
             visits.&#xD;
&#xD;
          -  IC7. Subject is expected to be able to take the protocol-required adjunctive&#xD;
             pharmacologic therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  EC1. Subject has a unicuspid or bicuspid aortic valve.&#xD;
&#xD;
          -  EC2. Subject has had an acute myocardial infarction within 30 days prior to the index&#xD;
             procedure (defined as Q-wave MI or non-Q-wave MI with total CK elevation ≥ twice&#xD;
             normal in the presence of CK-MB elevation and/or troponin elevation).&#xD;
&#xD;
          -  EC3. Subject has had a cerebrovascular accident or transient ischemic attack&#xD;
             clinically confirmed by a neurologist or neuroimaging within the past 6 months prior&#xD;
             to study enrollment.&#xD;
&#xD;
          -  EC4. Subject is on renal replacement therapy or has eGFR &lt;20.&#xD;
&#xD;
          -  EC5. Subject has a pre-existing prosthetic aortic or mitral valve.&#xD;
&#xD;
          -  EC6. Subject has severe (4+) aortic, tricuspid, or mitral regurgitation.&#xD;
&#xD;
          -  EC7. Subject has moderate or severe mitral stenosis (mitral valve area ≤1.5 cm2 and&#xD;
             diastolic pressure half-time ≥150 ms, Stage C or D76).&#xD;
&#xD;
          -  EC8. Subject has a need for emergency surgery for any reason.&#xD;
&#xD;
          -  EC9. Subject has a history of endocarditis within 6 months of index procedure or&#xD;
             evidence of an active systemic infection or sepsis.&#xD;
&#xD;
          -  EC10. Subject has echocardiographic evidence of new intra-cardiac vegetation or&#xD;
             intraventricular or paravalvular thrombus requiring intervention.&#xD;
&#xD;
          -  EC11. Subject has platelet count &lt;50,000 cells/mm3 or &gt;700,000 cells/mm3, or white&#xD;
             blood cell count &lt;1,000 cells/mm3.&#xD;
&#xD;
          -  EC12. Subject has had a gastrointestinal bleed requiring hospitalization or&#xD;
             transfusion within the past 3 months, or has other clinically significant bleeding&#xD;
             diathesis or coagulopathy that would preclude treatment with required antiplatelet&#xD;
             regimen, or will refuse transfusions.&#xD;
&#xD;
          -  EC13. Subject has known hypersensitivity to contrast agents that cannot be adequately&#xD;
             pre-medicated, or has known hypersensitivity to the protocol required medications&#xD;
             (aspirin, all P2Y12 inhibitors, heparin), or to the individual components of the test&#xD;
             or control valve (nickel, titanium, stainless steel, platinum, iridium or polyethylene&#xD;
             terephthalate [PET]).&#xD;
&#xD;
          -  EC14. Subject has a life expectancy of less than 12 months due to non-cardiac,&#xD;
             comorbid conditions based on the assessment of the investigator at the time of&#xD;
             enrollment.&#xD;
&#xD;
          -  EC15. Subject has hypertrophic cardiomyopathy.&#xD;
&#xD;
          -  EC16. Subject has any therapeutic invasive cardiac or vascular procedure within 30&#xD;
             days prior to the index procedure (except for balloon aortic valvuloplasty, pacemaker&#xD;
             implantation, or implantable cardioverter defibrillator implantation, which are&#xD;
             allowed).&#xD;
&#xD;
          -  EC17. Subject has untreated coronary artery disease, which in the opinion of the&#xD;
             treating physician is clinically significant and requires revascularization.&#xD;
&#xD;
          -  EC18. Subject has severe left ventricular dysfunction with ejection fraction &lt;20%.&#xD;
&#xD;
          -  EC19. Subject is in cardiogenic shock or has hemodynamic instability requiring&#xD;
             inotropic support or mechanical support devices.&#xD;
&#xD;
          -  EC20. Subject has arterial access that is not acceptable for the study device (test or&#xD;
             control) delivery systems as defined in the device (test or control) Directions For&#xD;
             Use.&#xD;
&#xD;
          -  EC21. Subject has either of the following:&#xD;
&#xD;
               -  Severe vascular disease that would preclude safe access (e.g., aneurysm with&#xD;
                  thrombus that cannot be crossed safely; marked tortuosity; significant narrowing&#xD;
                  of the abdominal aorta; severe unfolding of the thoracic aorta; or thick,&#xD;
                  protruding, ulcerated atheroma in the aortic arch), OR&#xD;
&#xD;
               -  Severe/eccentric calcification of the aortic annulus that would prevent safe&#xD;
                  implantation of the TAVR prosthesis.&#xD;
&#xD;
          -  EC22. Subject has current problems with substance abuse (e.g., alcohol, etc.) that may&#xD;
             interfere with the subject's participation in this study.&#xD;
&#xD;
          -  EC23. Subject is participating in another investigational drug or device study that&#xD;
             has not reached its primary endpoint or subject intends to participate in another&#xD;
             investigational device clinical trial within 12 months after index procedure.&#xD;
&#xD;
          -  EC24. Subject has untreated conduction system disorder (e.g., Type II second degree&#xD;
             atrioventricular block) that in the opinion of the treating physician is clinically&#xD;
             significant and requires a pacemaker implantation. Enrollment is permissible after&#xD;
             permanent pacemaker implantation.&#xD;
&#xD;
          -  EC25. Subject has severe incapacitating dementia.&#xD;
&#xD;
        Additional exclusion criteria apply to subjects considered for enrollment in the CT Imaging&#xD;
        Substudy as listed below.&#xD;
&#xD;
          -  AEC1. Subject has eGFR &lt;30 mL/min (chronic kidney disease stage IV or stage V)&#xD;
&#xD;
          -  AEC2. Subject has atrial fibrillation that cannot be rate controlled to ventricular&#xD;
             response rate &lt; 60 bpm.&#xD;
&#xD;
          -  AEC3. Subject is expected to undergo chronic anticoagulation therapy after the index&#xD;
             procedure.&#xD;
&#xD;
        Note: Subjects treated with short-term anticoagulation post procedure can be included in&#xD;
        the CT Imaging Substudy; in these subjects the 30-day imaging will be performed 30 days&#xD;
        after discontinuation of anticoagulation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raj R. Makkar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Heart Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael J. Reardon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Methodist DeBakey Heart &amp; Vascular Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lisa Currier</last_name>
    <phone>508-683-4927</phone>
    <email>Lisa.Currier@bsci.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Von Mering, MD</last_name>
      <phone>352-351-7337</phone>
      <email>govonmering@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Gregory Von Mering, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Banner Good Samaritan</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Prakash Balan, MD</last_name>
      <phone>602-521-3090</phone>
      <email>prakash.balan@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>Prakash Balan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HonorHealth Scottsdale Healthcare</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Rizik, MD</last_name>
      <phone>480-860-1919</phone>
      <email>davidrizik@aol.com</email>
    </contact>
    <investigator>
      <last_name>David Rizik, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>TMC HealthCare</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thomas Waggoner, MD</last_name>
      <phone>520-324-5512</phone>
      <email>tom.waggoner@pimaheart.com</email>
    </contact>
    <investigator>
      <last_name>Thomas Waggoner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Health Medical Center</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernesto Ruiz-Rodriguez, MD</last_name>
      <phone>216-744-5430</phone>
      <email>eruizrodz@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ernesto Ruiz-Rodriguez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scripps Clinic</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Teirstein, MD</last_name>
      <phone>858-824-5222</phone>
      <email>Teirstein.paul@scrippshealth.org</email>
    </contact>
    <investigator>
      <last_name>Paul Teirstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Somjot Brar, MD</last_name>
      <phone>323-783-3168</phone>
      <email>somjot.s.brar@kp.org</email>
    </contact>
    <investigator>
      <last_name>Somjot Brar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Heart Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raj Makkar, MD</last_name>
      <phone>310-423-3977</phone>
      <email>raj.makkar@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Raj R Makkar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Southard, MD</last_name>
      <phone>916-734-5639</phone>
      <email>jasouthard@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Southard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente - San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Rassi, MD</last_name>
      <phone>415-471-7750</phone>
      <email>andrew.rassi@kp.org</email>
    </contact>
    <investigator>
      <last_name>Andrew Rassi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rahul Sharma, MD</last_name>
      <phone>650-723-0180</phone>
      <email>rpsharma@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Rahul Sharma, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Denver Cardiology Associates PC</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lee MacDonald, MD</last_name>
      <phone>303-715-2210</phone>
      <email>bhulbert@southdenver.com</email>
    </contact>
    <investigator>
      <last_name>Lee MacDonald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lowell Satler, MD</last_name>
      <phone>202-877-5975</phone>
      <email>lowell.f.satler@medstar.net</email>
    </contact>
    <investigator>
      <last_name>Lowell Satler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Morton Plant Hospital</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Rovin, MD</last_name>
      <phone>727-447-5972</phone>
      <email>joshua.rovin@baycare.org</email>
    </contact>
    <investigator>
      <last_name>Joshua D Rovin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orlando Regional Medical Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vijaykumar Kasi, MD</last_name>
      <phone>407-841-6444</phone>
      <email>Vijay.Kasi@orlandohealth.com</email>
    </contact>
    <investigator>
      <last_name>Vijaykumar Kasi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital (Midtown)</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Piedmont Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivek Rajagopal, MD</last_name>
      <phone>404-605-6517</phone>
      <email>vivek.rajagopal@piedmont.org</email>
    </contact>
    <investigator>
      <last_name>Vivek Rajagopal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NorthShore University Health Study Coordinator</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>NorthShore University H Study Coordinator, MD</last_name>
      <phone>847-570-2250</phone>
      <email>jlevisay@northshore.org</email>
    </contact>
    <investigator>
      <last_name>Justin Levisay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advocate Christ Medical Center</name>
      <address>
        <city>Oak Lawn</city>
        <state>Illinois</state>
        <zip>60453</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ravi Ramana, MD</last_name>
      <phone>708-597-7656</phone>
      <email>rramana@heartcc.com</email>
    </contact>
    <investigator>
      <last_name>Ravi Ramana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. John's Hospital (Prairie)</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62769</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nilesh Goswami, MD</last_name>
      <phone>217-788-0706</phone>
      <email>ngoswami@prairieheart.com</email>
    </contact>
    <investigator>
      <last_name>Nilesh Goswami, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Hermiller, MD</last_name>
      <phone>317-338-6666</phone>
      <email>james.hermiller@ascension.org</email>
    </contact>
    <investigator>
      <last_name>James Hermiller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phillip Horwitz, MD</last_name>
      <phone>319-356-3689</phone>
      <email>phillip-horwitz@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Phillip Horwitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Union Memorial Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Wang, MD</last_name>
      <phone>410-554-2332</phone>
      <email>john.wang@medstar.net</email>
    </contact>
    <investigator>
      <last_name>John Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio Inglessis, MD</last_name>
      <phone>617-724-8052</phone>
      <email>iinglessis@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Ignacio Inglessis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tsuyoshi Kaneko, MD</last_name>
      <phone>617-732-7678</phone>
      <email>tkaneko2@bwh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Tsuyoshi Kaneko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikos Kakouros, MD</last_name>
      <phone>508-856-1014</phone>
      <email>nikolaos.kakouros@umassmed.edu</email>
    </contact>
    <investigator>
      <last_name>Nikos Kakouros, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stanley Chetcuti, MD</last_name>
      <phone>734-232-4276</phone>
      <email>chetcuti@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Stanley Chetcuti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William O'Neill, MD</last_name>
      <phone>313-916-1822</phone>
      <email>woneill1@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>William O'Neill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abbott Northwestern Hospital</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santiago Garcia, MD</last_name>
      <phone>612-863-3900</phone>
      <email>santiago.garcia@allina.com</email>
    </contact>
    <investigator>
      <last_name>Santiago Garcia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CentraCare Heart and Vascular Center</name>
      <address>
        <city>Saint Cloud</city>
        <state>Minnesota</state>
        <zip>56303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brian Stegman, MD</last_name>
      <phone>320-251-2700</phone>
      <email>brian.stegman@centracare.com</email>
    </contact>
    <investigator>
      <last_name>Brian Stegman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital-St. Paul</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mudassar Ahmed, MD</last_name>
      <phone>218-786-8364</phone>
      <email>mahmed@healtheast.org</email>
    </contact>
    <investigator>
      <last_name>Mudassar Ahmed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Barnes Jewish Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Deborah Heart and Lung Center</name>
      <address>
        <city>Browns Mills</city>
        <state>New Jersey</state>
        <zip>08015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Kovach, MD</last_name>
      <phone>609-893-1200</phone>
      <phone_ext>5034</phone_ext>
      <email>KovachR@Deborah.org</email>
    </contact>
    <investigator>
      <last_name>Richard Kovach, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Englewood Health</name>
      <address>
        <city>Englewood</city>
        <state>New Jersey</state>
        <zip>07631</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joseph DeGregorio, MD</last_name>
      <phone>973-743-1121</phone>
      <email>joseph.degregorio@ehmchealth.org</email>
    </contact>
    <investigator>
      <last_name>Joseph DeGregorio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Robert Wood Johnson Medical Center</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Russo, MD</last_name>
      <phone>732-235-7231</phone>
      <email>mr1533@rwjms.rutgers.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Russo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albany Medical Center</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sanjay Samy, MD</last_name>
      <phone>518-262-9777</phone>
      <email>samys@amc.edu</email>
    </contact>
    <investigator>
      <last_name>Sanjay Samy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montefiore-Jack D. Weiler Hospital</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Azeem Latib, MD</last_name>
      <phone>917-471-1201</phone>
      <email>mlatib@montefiore.org</email>
    </contact>
    <investigator>
      <last_name>Mohamed Azeem Latib, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaleida Health</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vijay Iyer, MD</last_name>
      <phone>716-829-2663</phone>
      <email>viyer@kaleidahealth.org</email>
    </contact>
    <investigator>
      <last_name>Vijay Iyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Annapoorna Kini, MD</last_name>
      <phone>212-241-4021</phone>
      <email>Annapoorna.Kini@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>Annapoorna Kini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center/NYPH</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamim Nazif, MD</last_name>
      <phone>212-342-2101</phone>
      <email>tmn31@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Tamim Nazif, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cornell Presbyterian - New York</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shing-Chiu Wong, MD</last_name>
      <phone>212-746-4644</phone>
      <email>scwong@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>Shing-Chiu Wong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Vavalle, MD</last_name>
      <phone>984-974-7921</phone>
      <email>john_vavalle@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>John Vavalle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Rinaldi, MD</last_name>
      <phone>704-355-2000</phone>
      <email>michael.rinaldi@carolinashealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Michael Rinaldi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University School of Medicine</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Zhao, MD</last_name>
      <phone>336-716-3161</phone>
      <email>dazhao@wakehealth.edu</email>
    </contact>
    <investigator>
      <last_name>David Zhao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lindner Center for Research and Education at Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Choo, MD</last_name>
      <phone>513-585-1777</phone>
      <email>joseph.choo@thechristhospital.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Choo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samir Kapadia, MD</last_name>
      <phone>216-444-6735</phone>
      <email>kapadis@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Samir Kapadia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Carmel Columbus Cardiology Consultants</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>OhioHealth Research and Innovation Institute</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Yakubov, MD</last_name>
      <phone>614-566-5149</phone>
      <email>steven.yakubov@ohiohealth.com</email>
    </contact>
    <investigator>
      <last_name>Steven Yakubov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Integris Baptist Medical Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Chrysant, MD</last_name>
      <phone>405-917-3535</phone>
      <email>gsc5@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>George Chrysant, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Heart Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ethan Korngold, MD</last_name>
      <phone>503-216-0900</phone>
      <email>ethan.korngold@providence.org</email>
    </contact>
    <investigator>
      <last_name>Ethan Korngold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sacred Heart Medical Center - Riverbend</name>
      <address>
        <city>Springfield</city>
        <state>Oregon</state>
        <zip>97477</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sudeshna Banerjee, MD</last_name>
      <phone>541-484-4332</phone>
      <email>sbanerjee@peacehealth.org</email>
    </contact>
    <investigator>
      <last_name>Sudeshna Banerjee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC - Pinnacle</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hemal Gada, MD</last_name>
      <phone>717-731-0101</phone>
      <email>gadah@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Hemal Gada, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ibrahim Sultan, MD</last_name>
      <phone>412-623-2994</phone>
      <email>sutlani@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Ibrahim Sultan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lankenau</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19086</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Gnall, MD</last_name>
      <phone>484-476-1000</phone>
      <email>gnalle@mlhs.org</email>
    </contact>
    <investigator>
      <last_name>Eric Gnall, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>WellSpan York Hospital</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>James Harvey, MD</last_name>
      <phone>717-851-2441</phone>
      <email>jharvey3@wellspan.org</email>
    </contact>
    <investigator>
      <last_name>James Harvey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel Steinberg, MD</last_name>
      <phone>843-876-4747</phone>
      <email>steinbe@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Steinberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lexington Medical Center</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Leonardi, MD</last_name>
      <phone>803-744-4900</phone>
      <email>raleonardi@lexhealth.org</email>
    </contact>
    <investigator>
      <last_name>Robert Leonardi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Thomas Ascension</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael A Morse, MD</last_name>
      <phone>615-269-4545</phone>
      <email>andrew.morse@ascension.org</email>
    </contact>
    <investigator>
      <last_name>Michael A Morse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Austin Heart</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Moscona, MD</last_name>
      <phone>512-206-3600</phone>
      <email>john.moscona@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>John Moscona, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Heart and Vascular Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Stoler, MD</last_name>
      <phone>214-820-9903</phone>
      <email>rcstoler@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Robert Stoler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Presbyterian Hospital of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Park, MD</last_name>
      <phone>214-369-3613</phone>
      <email>jamespark@texashealth.org</email>
    </contact>
    <investigator>
      <last_name>James Park, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital Research Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neil Kleiman, MD</last_name>
      <phone>713-441-1100</phone>
      <email>NKleiman@houstonmethodist.org</email>
    </contact>
    <investigator>
      <last_name>Neil Kleiman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abhijeet Dhoble, MD</last_name>
      <phone>713-500-6550</phone>
      <email>abhijeet.dhoble@uth.tmc.edu</email>
    </contact>
    <investigator>
      <last_name>Abhijeet Dhoble, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Regional Medical Center at Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Srinivasa Potluri, MD</last_name>
      <phone>469-800-6300</phone>
      <email>srinivasa.potluri@bswhealth.org</email>
    </contact>
    <investigator>
      <last_name>Srinivasa Potluri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The University of Vermont Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harold Dauerman, MD</last_name>
      <phone>802-847-3734</phone>
      <email>harold.dauerman@uvmhealth.org</email>
    </contact>
    <investigator>
      <last_name>Harold Dauerman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Scott Lim, MD</last_name>
      <phone>434-982-1058</phone>
      <email>SL9PC@hscmail.mcc.virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Scott Lim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sentara Norfolk General Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Mahoney, MD</last_name>
      <phone>757-388-5480</phone>
      <email>paul.mahoney.md@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Paul Mahoney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Regional Medical Center</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Apurva Badheka, MD</last_name>
      <phone>452-339-5431</phone>
      <email>abadheka@everettclinic.com</email>
    </contact>
    <investigator>
      <last_name>Apurva Badheka, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bellin Health</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jason Ricci, MD</last_name>
      <phone>920-433-3640</phone>
      <email>jason.ricci@bellin.org</email>
    </contact>
    <investigator>
      <last_name>Jason Ricci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aurora Research Institute</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanvir Bajwa, MD</last_name>
      <phone>414-649-6180</phone>
      <email>tanvir.bajwa@aah.org</email>
    </contact>
    <investigator>
      <last_name>Tanvir Bajwa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin - Froedtert Hospital</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Salinger, MD</last_name>
      <phone>414-955-6990</phone>
      <email>msalinger@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Salinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Columbian Hospital</name>
      <address>
        <city>New Westminster</city>
        <state>British Columbia</state>
        <zip>V3L 3W5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Albert Chan, MD</last_name>
      <phone>(604) 520-3858</phone>
      <email>albert.chan@fraserhealth.ca</email>
    </contact>
    <investigator>
      <last_name>Albert Chan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Health - St. Paul's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Webb, MD</last_name>
      <phone>604-682-2344</phone>
      <email>webb@providencehealth.bc.ca</email>
    </contact>
    <investigator>
      <last_name>John Webb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Health Sciences</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pantelis Diamantouros, MD</last_name>
      <phone>519-685-8500</phone>
      <phone_ext>33329</phone_ext>
      <email>pantelis.diamantouros@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Pantelis Diamantouros, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaym Radhakrishnan, MD</last_name>
      <phone>(416) 480-5827</phone>
      <email>sam.radhakrishnan@sunnybrook.ca</email>
    </contact>
    <investigator>
      <last_name>Shaym Radhakrishnan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Universite de Montreal (CHUM)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3E4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeannot Potvin, MD</last_name>
      <phone>+61 3 9594 4543</phone>
      <email>jeannotpotvin@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Jeannot Potvin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cardiologie de Montreal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Reda Ibrahim, MD</last_name>
      <phone>(514) 376-3330</phone>
      <email>Reda.Ibrahim@icm-mhi.org</email>
    </contact>
    <investigator>
      <last_name>Reda Ibrahim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie et de Pneumologie de Quebec (IUCPQ)</name>
      <address>
        <city>Québec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Josep Rodés-Cabau, MD</last_name>
      <phone>418-656-8711</phone>
      <email>josep.rodes@criucpq.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Josep Rodés-Cabau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 6, 2018</study_first_submitted>
  <study_first_submitted_qc>November 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2018</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>The data and study protocol for this clinical trial may be made available to other researchers in accordance with the Boston Scientific Data Sharing Policy (http://www.bostonscientific.com/en-US/data-sharing-requests.html)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

